PHARMACEUTICAL CONFERENCES
Join Thomson Reuters researchers at key pharmaceutical industry events as they share relevant findings of their most recent healthcare research.
MAY 2012
Quality of Care and Outcomes Research 2012 Scientific Sessions
May 9-11
Atlanta, GA
Smoyer-Tomic KE, Siu K, Johnson B, Walker D, Sander S, Song X, Amin A. Readmission among hospitalized patients with non-valvular atrial fibrillation.
Society of General Internal Medicine (SGIM) 35th Annual Meeting
May 9-12
Orlando, FL
Haas G, Johnston S, Janning S, Wilson K, Smith D, Reckard GM, Quan SP, Bukofzer S. Overactive bladder medications: Comparative persistence and adherence of patients with and without diabetes.
JUNE 2012
ASCO Annual '12 Meeting
June 1-5
Chicago, IL
Landsman-Blumberg P, Namjoshi M, Thomson E, Johnson W. Real-world aromatase inhibitor use and failure in women with metastatic ER+/HER2- breast cancer.
7th International Conference on HIV Treatment and Prevention Adherence, Miami, FL
June 3-5
Johnston S, Juday T, Esker S, Espindle D, Chu BC, Hebden T, Uy J.
Tolerability of atazanavir- versus darunavir-based combination antiretroviral therapy among U.S. Medicaid HIV patients.
ISPOR 17th Annual International Meeting
June 2-6
Washington, DC
ISSUE PANELS
Monday, June 4, 2012
10:45-11:45
Dubois RW, Gibson TB, Timbie J, Slutsky J.
What have we learned in the translation and dissemination of comparative effectiveness research? (IP1)
POSTER SESSION I
Monday, June 4, 2012
8:30 AM - 2:00 PM
Gibson TB, Mahoney J, Lucas K, Heithoff K, Gatwood J. Value-based design and prescribing patterns. (PHP 3)
Foley K, Carls G, Roberto P. Medication adherence and medical cost offsets: A review of the literature. (PHP42)
Huse D, Marder WD. Recent growth in employer health care spending by disease: an update. (PHP53)
Lian JF, Song X, Varker H, Cao Z, Recknor CP. Comparative effectiveness analysis using “real-world” patient database to evaluate the fractures rates comparing annual zoledronic acid infusion with oral bisphosphonates. (PMS3)
Bonafede M, Gandra SR, Watson C, Princic N, Fox KM. Cost of tumor necrosis factor blocker per treated psoriatic arthritis patient using drug utilization data from a US managed care population. (PMS16)
Bonafede M, Espindle D, Bower T. The direct and indirect costs of long bone fractures in a working age population in the United States. (PMS18)
Bonafede M, Gandra SR, Watson C, Princic N, Fox KM. Cost per treated rheumatoid arthritis (RA) patient for etanercept, adalimumab, and infliximab: A retrospective claims database analysis. (PMS23)
Durden E, Maiese BA, Essex MN, Cappelleri JC, Joshi AV. Association between restrictions on celecoxib use and health care utilization and costs in Medicare beneficiaries with arthritis. (PMS67)
Bonafede B, Watson C, Fox KM, Wilson KL, Gandra S. Anti-tumor necrosis factor dose escalation among biologic naïve rheumatoid arthritis (RA) ratients in commercial managed care plans in the two years following therapy initiation. (PMS69)
Krilov LR, Weiner LB, Wade SW, Smith DM, Masaquel A. Non-compliance with palivizumab and increased risk of respiratory syncytial virus hospitalization among a Medicaid population. (PRS11)
Landsman-Blumberg PB, Wei W. Douglas D, Smith D, Camargo CA. A large-scale retrospective study of emergency department visits or hospitalizations for anaphylaxis among patients with employer- sponsored health insurance. (PRS45)
POSTER SESSION II
Monday, June 4, 2012
4:30 PM - 8:30 PM
Bernauer M, Farr A, Haynes V, Montejano LB, Lenhart G, Pohl G, Kelsey. Combination utilization patterns and treatment predictors in ADHD in a commercially insured population. (PMH19)
Mark T, Steiner C, Lawrence W, Coffey R, Chu BC, Kenney T, Nagamine M, Zheng D. Open versus endovascular repair for abdominal aortic aneurysm: An exploration with discharge and post-discharge-mortality data. (PSU4)
Kan H, Song X, Bechtel B, Johnson BH, O’Sullivan D, Molta C. Health care resource utilization (HRU) and costs associated with flares in patients with systemic lupus erythematosus (SLE) in a Medicaid population in the United States. (PSY25)
Tomic KS, Amato AA, Fernandes A. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations. (PSY10)
POSTER SESSION IV
Tuesday, June 5, 2012
3:45 PM - 7:45 PM
Curkendall SM, Zhang B, Lenhart G, Thomson E, Bell K, Graham J. Comparing hypoglycemia rates for type 2 diabetes patients treated with saxagliptin vs. sulfonylurea: using claims data to replicate a clinical trial. (PDB1)
Juneau P. Diagnostic tools for the assessment of the underlying model assumptions in the study of health care costs. (PRM48)
POSTER SESSION V
Wednesday, June 6, 2012
8:30 AM - 2:45 PM
Johnston SS, Juday T, Espindle D, Chu BC, Hebden T. Impact of at-risk window assignment on retrospectively-estimated incidence and costs of safety and tolerability among Medicaid HIV patients initiating protease inhibitor-based combination antiretroviral therapy in the United States. (PIN67)
Curkendall SM, Bonthapally V, Meyer NM, Miller JD, Bonafede MM, Ray S. Direct medical costs associated with different lines of therapy for colorectal cancer (CRC) patients. (PCN39)
Landsman-Blumberg P, Namjoshi M, Thomson E, Johnson W. Real-world aromatase inhibitor use and failure in women with metastatic ER+/HER2- breast cancer. (PCN 121)
Tomic KS, Long S, Li X, Yu J, Fu AC, Barron R. Patients' out-of-pocket (OOP) costs for granulocyte colony-stimulating factors (G-CSF). (PCN131)
Foley K. Designing case report forms for economic evaluation along side clinical trials: A case-study using an interactive data analysis tool to streamline data collection. (PCN151)
Bonafede M, Juday T, Lenhart G, Pan K, Hebden T, Correll T. Cost-effectiveness of efavirenz versus rilpivirine in HIV patients initiating first-line treatment in the United States. (PIN25)
WORKSHOPS - SESSION IV
Wednesday, June 6, 2012
1:45 PM - 2:45 PM
Gagnon D, Englehart L.
Estimating cost-effectiveness ratios from clinical trials with missing data: a comparison of the Kaplan-Meier sample average statistic and the joint mixed-effects and logged time-to-dropout model (W23)
4th Biennial Conference of the American Society of Health Economists
June 10-13
Minneapolis/St. Paul, MN
Mark T. Health Reform and Behavioral Health: What Might We Expect?